All Posts

Cancer Vaccine on the Cards

Aug 20, 2026

•

3 min read

The Healthcare Cerberus Just Woke Up

Aug 19, 2026

•

3 min read

The Orphan Drug Playbook: The Neuren Story (NEU)

Aug 18, 2026

•

10 min read

Reporting Season: What I look for in Annual Reports

Aug 17, 2026

•

8 min read

Two weeks to go...

Aug 14, 2026

•

2 min read

Back the Jockey: The Alterity Story (ASX: ATH)

Aug 13, 2026

•

8 min read

Day 2 of Bioshares: One Year On...

Aug 7, 2026

•

2 min read

Eli Lilly's $23 Billion Shopping Spree

Aug 6, 2026

•

1 min read

Day 1 of Bioshares: It’s Snow Problem

Aug 5, 2026

•

1 min read

The Money Equation for Biotechs

Aug 4, 2026

•

8 min read

Time is Brain: The EMVision Story (EMV)

Aug 3, 2026

•

9 min read

Control Bionics: A Quarter’s Worth of Progress

Jul 31, 2026

•

5 min read

1 2 3...15

All Posts

Cancer Vaccine on the Cards

The Healthcare Cerberus Just Woke Up

The Orphan Drug Playbook: The Neuren Story (NEU)

Reporting Season: What I look for in Annual Reports

Two weeks to go...

Back the Jockey: The Alterity Story (ASX: ATH)

Day 2 of Bioshares: One Year On...

Eli Lilly's $23 Billion Shopping Spree

Day 1 of Bioshares: It’s Snow Problem

The Money Equation for Biotechs

Time is Brain: The EMVision Story (EMV)

Control Bionics: A Quarter’s Worth of Progress

The Armchair Analyst